原发性硬化性胆管炎的综合综述
本文全面综述原发性硬化性胆管炎(PSC)的现状,强调患者分层与疾病行为相关进展,从以患者为中心的角度概述管理选择,并总结基于发病机制认识开发有效疗法的持续努力。
要点
- PSC以多灶性胆管狭窄和进行性肝病为特征,常合并炎症性肠病,胆管癌和结直肠癌风险高。
- 多数患者最终需肝移植,移植后可能复发,治疗选择有限且缺乏经验证的监测策略。
- 综述强调患者分层与疾病行为,并总结基于发病机制开发有效疗法的进展。
核心结论
- PSC患者目前存在显著未满足的医疗需求,治疗选择有限且缺乏经验证的监测策略。
研究设计与样本
- 本文为综合性综述,涵盖患者分层、疾病行为、管理选择及发病机制相关治疗进展。
主要发现
- PSC以多灶性胆管狭窄和进行性肝病为特征,常合并炎症性肠病,胆管癌和结直肠癌风险高。
- 多数患者最终需肝移植,移植后可能复发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary sclerosing cholangitis (PSC) is a rare disorder characterised by multi-focal bile duct strictures and progressive liver disease. Inflammatory bowel disease is usually present and there is a high risk of cholangiocarcinoma and colorectal cancer. Most patients ultimately require liver transplantation, after which disease recurrence may occur. With limited therapeutic options and a lack of proven surveillance strategies, patients currently have significant unmet needs. In the present seminar, we provide a comprehensive review of the status of the field. We emphasise developments related to patient stratification and disease behaviour, and provide an overview of management options from a practical, patient-centered perspective. We survey advances made in the understanding of PSC pathogenesis and summarise the ongoing efforts to develop an effective therapy based on these insights.
引用
- Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017. PMID: 28802875. doi:10.1016/j.jhep.2017.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。